Reference Detail

Ref Type
PMID
Authors Howard Colman, Jeffrey Raizer, Tobias Walbert, Scott Plotkin, Marc Chamberlain, Eric Wong, Vinay Puduvalli, David Reardon, Fabio Iwamoto, Brett Johnson, Karthik Sonty, Bill Welbourn, David Karlin, Michael Pelayo, Marguerite Hutchinson et. al.
Title INITIAL RESULTS OF PLX108-08: AN OPEN LABEL PHASE 1B/2 STUDY OF ORALLY ADMINISTERED PEXIDARTINIB (PLX3397) IN COMBINATION WITH RADIATION THERAPY AND TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA
Journal Neuro Oncol
Vol
Issue
Date
URL http://neuro-oncology.oxfordjournals.org/content/18/suppl_6/vi6.1.abstract?sid=4bb3de14-d380-4d46-a482-fff2514faa51
Abstract Text Neuro Oncol (2016) 18 (suppl 6): vi6.

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Treatment Approach
Gene Name Source Synonyms Protein Domains Gene Description Gene Role
Therapy Name Therapy Description
Drug Name Trade Name Synonyms Drug Classes Drug Description
Variant Impact Protein Effect Variant Description Associated with drug Resistance
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown glioblastoma multiforme not applicable Pexidartinib Phase II Actionable In a Phase II trial, PLX3397 in combination with radiation therapy and Temodar (temozolomide) demonstrated safety and improved efficacy over standard therapy, resulted in a median progression free survival of 9.7 months and an estimated overall survival of 25.1 months in newly diagnosed glioblastoma multiforme patients (Neuro Oncol (2016) 18 (suppl 6): vi6.). detail...